Video: Dr. Yoo-Joung Ko discusses results from the safety run in of a randomized phase II study of gemcitabine (gem) and nab-paclitaxel (nab-P) versus gem, nab-P, durvalumab, and tremelimumab as first-line therapy in mPDAC

Show All
/
leukemia
/
Lung
/
lymphoma
/
Pancreatic